Summary of project PR000383
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000383. The data can be accessed directly via it's Project DOI: 10.21228/M8JG7B This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR000383 |
| Project DOI: | doi: 10.21228/M8JG7B |
| Project Title: | Mayo Metabolomics Pilot and Feasibility Award: Role of muscle insulin and IGF-1 signaling on serum and muscle metabolite profiles |
| Project Summary: | Skeletal muscle insulin resistance is a cardinal feature of the pathogenesis of type 2 diabetes. Insulin and IGF-1 signal through their highly related receptors to impact on many aspects of muscle physiology including glucose homeostasis, protein metabolism, and mitochondrial function. Early physiological studies, as well as recent large scale metabolomic studies, have shown that changes in specific pools of circulating amino acid metabolites, such as branched chain amino acids (BCAAs), are associated with insulin resistance and can predict future diabetes, but the source and impact of these changes in amino acids are not fully understood. We have recently generated mice which lack insulin receptors (IR) or IGF-1 receptors (IGF1R) or both in muscle using Cre lox recombination. We find that mice which lack only IR or only IGF1R in muscle show minimal changes in muscle mass, but do display increases in proteasomal activity and autophagy in muscle. On the other hand, mice with combined loss of both IR and IGF1R display markedly decreased muscle mass and enhanced degradation pathways, associated with increased protein synthesis, and display changes in mitochondrial gene regulation, indicating that both receptors can compensate to some extent for loss of the other. We hypothesize that IR and IGF1R signaling in muscle coordinate amino acid metabolite turnover and fuel substrate/mitochondrial metabolism, and that in insulin resistant states, changes in protein metabolism and mitochondrial function disrupt relative proportions of amino acid metabolites, which in turn contribute to diabetes risk and/or muscle pathology. We propose to test this hypothesis by performing large scale metabolomics on serum and muscle from mice lacking IR, IGF1R or both in muscle, and we will compare these changes to both insulin deficient streptozotocin-treated and insulin resistant diet-induced obese mouse models. To gain insight into which pathways are critical for metabolite changes, we will also treat mice with specific inhibitors of mTOR, a common protein synthesis pathway, as well as inhibitors of autophagy or proteasomal degradation and determine metabolite concentrations in muscle and serum. These studies will identify specific pathways that impact amino acid and mitochondrial metabolite flux which are perturbed in insulin resistant states, and potentially provide insights into how changes in amino acid metabolites contribute to diabetes risk. |
| Institute: | Mayo Clinic |
| Last Name: | O'Neill |
| First Name: | Brian |
| Address: | One Joslin Place, Boston, MA 02215 |
| Email: | brian.o'neill@joslin.harvard.edu |
| Phone: | 617-309-2400 |
Summary of all studies in project PR000383
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST000511 | Determine how inhibition of autophagy/proteasome degradation or inhibition of protein synthesis in models of muscle insulin resistance affect amino acid metabolites | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 46 | Not available |
| ST000512 | Investigating TCA concentrations in mice muscle tissue lacking insulin receptors and IGF-1 receptors | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 37 | Not available |
| ST000513 | Inhibition of autophagy/proteasome degradation or inhibition of protein synthesis in models of muscle insulin resistance affect TCA cycle | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 46 | Not available |
| ST000514 | Inhibition of autophagy/proteasome degradation or inhibition of protein synthesis in models of muscle insulin resistance affect amino acids metabolites in serum | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 36 | Not available |
| ST000516 | Measuring amino acid metabolites in insulin resistant and insulin deficient mouse tissue models | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 36 | Not available |
| ST000517 | Measuring acylcarnitine concentrations in insulin resistant and insulin deficient mouse tissue models | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 36 | Not available |
| ST000518 | Measuring ceramide concentrations in insulin resistant and insulin deficient mouse tissue models | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 36 | Not available |
| ST000519 | Investigating ceremide concentrations in mice muscle tissue lacking insulin receptors and IGF-1 receptors | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 27 | Not available |
| ST000520 | Measuring TCA cycle concentrations in insulin resistant and insulin deficient mouse tissue models | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 39 | Not available |
| ST000521 | Measuring NEFA concentrations in insulin resistant and insulin deficient mouse tissue models | Mus musculus | Mayo Clinic | MS | 2018-12-11 | 1 | 39 | Not available |
| ST000549 | Investigating large scale metabolomics in mice serum lacking insulin receptors and IGF-1 receptors | Mus musculus | Mayo Clinic | MS | 2019-03-06 | 1 | 148 | Not available |
| ST000551 | Investigating large scale metabolomics in mice tissue lacking insulin receptors and IGF-1 receptors | Mus musculus | Mayo Clinic | MS* | 2019-03-06 | 1 | 148 | Not available |
